The development of drug and biological products intended to treat rare diseases (Orphan diseases) is one of the fastest growing areas of clinical research, and also one of the most challenging. This article provides an introduction to two important regulatory considerations for Orphan drugs: Orphan status designations and general considerations for the administration of investigational agents in early phase clinical trials. Incentives available to orphan drug developers under the Orphan Drug Act (ODA) and requirements for obtaining an orphan status designation are discussed. An introductory overview of ethical and statutory considerations for investigational drugs, requirements for initiating investigational new drug applications (INDs), and sources of information and advice from the US Food and Drug Administration (FDA) are also described.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Exploring the Potential of Nanocarriers for Cancer Immunotherapy: Insights into Mechanism, Nanocarriers, and Regulatory Perspectives.
ACS Appl Bio Mater
January 2025
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad 500037, India.
Immunotherapy is a cutting-edge approach that leverages sophisticated technology to target tumor-specific antibodies and modulate the immune system to eradicate cancer and enhance patients' quality of life. Bioinformatics and genetic science advancements have made it possible to diagnose and treat cancer patients using immunotherapy technology. However, current immunotherapies against cancer have limited clinical benefits due to cancer-associated antigens, which often fail to interact with immune cells and exhibit insufficient therapeutic targeting with unintended side effects.
View Article and Find Full Text PDFUnity in Diversity and Diversity in Unity-Vaccination Policies in EU Countries.
Healthcare (Basel)
December 2024
Department of Organization and Economy of Pharmacy, Faculty of Pharmacy, Medical University-Sofia, 1504 Sofia, Bulgaria.
Background/objectives: This article emphasizes the comprehensive importance of vaccination, exploring its role in disease prevention, addressing growing concerns around vaccine hesitancy, and underscoring the crucial need for high vaccination coverage rates.
Methods: Our review examines EU-level and national policies on vaccination, utilizing EU sources, with a specific focus on regulatory and policy documents. Vaccination calendars in the EU were reviewed through the ECDC Vaccine Scheduler webpage.
Mandatory Requirements for Planning and Commissioning of Medical Cyclotron Facility.
Indian J Nucl Med
November 2024
Health Physics Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India.
Over the last 15 years, there has been substantial growth in the installation of medical cyclotrons. This is mainly due to the increased demand for the production of positron emission tomography radiopharmaceuticals. In every country, there is a regulatory body that regulates the uses of medical cyclotron intending to protect occupational workers, the public, and the environment.
View Article and Find Full Text PDFA weight of evidence review on the mode of action, adversity, and the human relevance of xylene's observed thyroid effects in rats.
Crit Rev Toxicol
January 2025
Product Stewardship, Science & Regulatory, Shell Global Solutions International B.V. The Hague, the Netherlands.
Xylene substances have wide industrial and consumer uses and are currently undergoing dossier and substance evaluation under Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) for further toxicological testing including consideration of an additional neurotoxicological testing cohort to an extended one-generation reproduction toxicity (EOGRT) study. New repeated dose study data on xylenes identify the thyroid as a potential target tissue, and therefore a weight of evidence review is provided to investigate whether or not xylene-mediated changes on the hypothalamus-pituitary-thyroid (HPT) axis are secondary to liver enzymatic induction and are of a magnitude that is relevant for neurological human health concerns. Multiple published studies confirm xylene-mediated increases in liver weight, hepatocellular hypertrophy, and liver enzymatic induction the oral or inhalation routes, including an increase in uridine 5'-diphospho-glucuronosyltransferase (UDP-GT) activity, the key step in thyroid hormone metabolism in rodents.
View Article and Find Full Text PDFWhat should constitute a control condition in psychedelic drug trials?
Nat Ment Health
October 2024
Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Over the past decade there has been a surge in interest in placebo-controlled trials using non-classical 3,4-methylenedioxymethamphetamine (MDMA) and classical psychedelics such as psilocybin, lysergic acid diethylamide (LSD) and ,-dimethyltryptamine (DMT) to treat neuropsychiatric disorders. However, the success and reliability of these trials depend on the design of the trials, the choice of control conditions, and the ability to blind both participants and researchers. When appropriate control conditions are lacking, it becomes difficult to disentangle placebo and expectation effects from medication effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!